Edit |   |
---|---|
Antigenic Specificity | PD-1 |
Clone | [IHC001] |
Host Species | Mouse |
Reactive Species | human |
Isotype | n/a |
Format | unconjugated |
Size | 0.1 mL (Concentrate), 7 mL (Prediluted), 1 mL (Concentrate) |
Concentration | n/a |
Applications | n/a |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Intended Use: The PD-1 [IHC001] antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed, paraffin-embedded tissue sections using IHC test methods. Description: Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumor immunity, as PD-L1 has been shown to induce apoptosis of activated T cells or inhibit activity of cytotoxic T cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B cells and has therefore been considere |
Immunogen | n/a |
Other Names | [programmed cell death protein 1; Programmed cell death protein 1; programmed cell death protein 1; programmed cell death 1; CD_antigen: CD279], [PDCD1; PDCD1; PD1; PD-1; CD279; SLEB2; hPD-1; hPD-l; hSLE1; PD1; Protein PD-1; hPD-1] |
Gene, Accession # | [PD-1], Gene ID: 5133, NCBI: NP_005009.2, UniProt: Q15116 |
Catalog # | MBS344001 |
Price | $165, $225, $245 |
Order / More Info | PD-1 Antibody from MYBIOSOURCE INC. |
Product Specific References | 1. Dorfman DM, et al. Am J Surg Pathol. 2006; 30:802-10.2. Hamanishi J, et al. Proc Natl Acad Sci USA. 2007; 104:3360-5.3. Kobayashi M, et al. J Rheumatol. 2005; 32:2156-63.4. Konishi J, et al. Clin Cancer Res. 2004; 10:5094-100.5. Mataki N, et al. Am J Gastroenterol. 2007; 102:302-12.6. Kim JW, et al. Oncology (Williston Park). 2014; 28:15-28.7. Tumeh PC, et al. Nature. 2014; 515:568-71.8. D'Incecco A, et al. Br J Cancer. 2015; 112:95-102.9. Tykodi SS. Onco Targets Ther. 2014; 7:1349-59. |